NASDAQ:VCEL - Vericel Stock Price, News & Analysis

$16.32
+0.73 (+4.68 %)
(As of 08/18/2019 08:56 AM ET)
Today's Range
$15.70
Now: $16.32
$16.42
50-Day Range
$15.2559
MA: $18.74
$19.83
52-Week Range
$10.30
Now: $16.32
$21.00
Volume456,100 shs
Average Volume491,787 shs
Market Capitalization$720.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2.75
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCEL
CUSIPN/A
Phone800-556-0311

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.86 million
Book Value$2.01 per share

Profitability

Net Income$-8,140,000.00

Miscellaneous

Employees216
Market Cap$720.36 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.


Vericel (NASDAQ:VCEL) Frequently Asked Questions

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

How were Vericel's earnings last quarter?

Vericel Corp (NASDAQ:VCEL) posted its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.42. The biotechnology company earned $26.15 million during the quarter, compared to analysts' expectations of $24.13 million. Vericel had a negative return on equity of 0.99% and a negative net margin of 18.14%. The business's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.12) earnings per share. View Vericel's Earnings History.

When is Vericel's next earnings date?

Vericel is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Vericel.

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $112-116 million, compared to the consensus revenue estimate of $113.22 million.

What price target have analysts set for VCEL?

3 brokers have issued 12-month price objectives for Vericel's stock. Their predictions range from $17.92 to $32.00. On average, they anticipate Vericel's stock price to reach $24.64 in the next year. This suggests a possible upside of 51.0% from the stock's current price. View Analyst Price Targets for Vericel.

What is the consensus analysts' recommendation for Vericel?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.

Has Vericel been receiving favorable news coverage?

Headlines about VCEL stock have been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vericel earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Vericel.

Who are some of Vericel's key competitors?

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Synergy Pharmaceuticals (SGYP), Momo (MOMO), Exelixis (EXEL), Novavax (NVAX), NVIDIA (NVDA), Dynavax Technologies (DVAX), Amarin (AMRN), Verastem (VSTM), ACADIA Pharmaceuticals (ACAD) and Adamis Pharmaceuticals (ADMP).

Who are Vericel's key executives?

Vericel's management team includes the folowing people:
  • Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 55)
  • Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 56)
  • Mr. Daniel R. Orlando, Chief Operating Officer (Age 54)
  • Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
  • Ms. Heidi Hassen, Sr. Director of HR

Who are Vericel's major shareholders?

Vericel's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.18%), Vanguard Group Inc. (5.91%), Waddell & Reed Financial Inc. (4.58%), Nuveen Asset Management LLC (1.94%), Redwood Investments LLC (1.90%) and Emerald Advisers LLC (1.77%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.

Which institutional investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Acadian Asset Management LLC, Parametric Portfolio Associates LLC, Kopp Investment Advisors LLC, Panagora Asset Management Inc., Bank of America Corp DE, Essex Investment Management Co. LLC and AQR Capital Management LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Insider Buying and Selling for Vericel.

Which institutional investors are buying Vericel stock?

VCEL stock was acquired by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., Nuveen Asset Management LLC, Redwood Investments LLC, SG Capital Management LLC, Fort Washington Investment Advisors Inc. OH, GW&K Investment Management LLC, Calamos Advisors LLC and Emerald Advisers LLC. View Insider Buying and Selling for Vericel.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $16.32.

How big of a company is Vericel?

Vericel has a market capitalization of $720.36 million and generates $90.86 million in revenue each year. The biotechnology company earns $-8,140,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Vericel employs 216 workers across the globe.View Additional Information About Vericel.

What is Vericel's official website?

The official website for Vericel is http://www.vcel.com/.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]


MarketBeat Community Rating for Vericel (NASDAQ VCEL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel